Skip to main content
. 2022 Aug 23;20(3):2693. doi: 10.18549/PharmPract.2022.3.2693

Table 2.

Drugs’ indication, dosage appropriateness and co-prescribed drugs, n=291

Cohort Pregabalin Gabapentin
N (%) 291 247 (84.8) 44 (15.1)
Indications labelled 63 (21.6) 61 (24.7) 2 (4.5)
Diabetic peripheral neuropathy 50 (79.4) 49 (80.3) 1 (50.0)
Fibromyalgia 10 (15.9) 10 (16.4)
Postherpetic neuralgia 3 (4.7) 2 (3.3) 1 (50.0)
Off-label 159 (54.6) 128 (51.8) 31(70.5)
Lower back pain 47 (29.6) 43 (33.6) 4 (12.9)
Spinal cord injury 16 (10.1) 13 (10.2) 3 (9.7)
Others 83 (52.2) 72 (56.3) 11 (35.5)
undocumented 69 (23.7) 58 (23.5) 11 (25.0)
Dosage appropriateness 291 (100) 247 (100) 44 (100)
Co-prescribed drugs
Aspirin 78 (26.8) 70 (28.3) 8 (18.2)
Metformin 68 (23.4) 58 (23.5) 10 (22.7)
Esomeprazole 63 (21.6) 54 (21.9) 9 (20.5)
Paracetamol 61 (21.0) 49 (19.8) 12 (27.3)
Rosuvastatin 59 (20.3) 50 (20.2) 9 (20.5)
Atorvastatin 44 (15.1) 44 (17.8)
Celecoxib 34 (11.7) 34 (13.8)
Co-prescribed controlled drugs
Tramadol 18 (6.2) 16 (6.5) 2 (4.5)
Co-codamol 12 (4.1) 10 (4.0) 2 (4.5)
Duloxetine 9 (3.1) 7 (2.8) 2 (4.5)
Fluoxetine 5 (1.7) 3 (1.2) 2 (4.5)
Others 10 (3.4) 8 (3.2) 2 (4.5)

Some data do not add up to 100% as some were missing